Summary:
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Criteria:Age 18 and older
Have an increased risk of cardiac events
BMI of ≥25
Have Type 2 Diabetes
Qualified Participants May Receive:
Compensation for time and travel
Medication and procedures covered